# ASIRI SURGICAL HOSPITAL PLC Financial Summary

Canonical URL: https://pal.lk/updates/amsl-financial-summary
Symbol: AMSL.N0000
Company: ASIRI SURGICAL HOSPITAL PLC
Sector: Health Care Equipment & Services
Published: 2026-08-31T20:09:05Z
Last updated: 2026-08-31T20:09:05Z

# Asiri Surgical Hospital PLC Financial Summary and Investment Analysis

## Executive Overview
Asiri Surgical Hospital PLC (AMSL.N0000) is a premier private sector surgical hospital in Sri Lanka, operating as a subsidiary of Asiri Hospital Holdings PLC (part of the Softlogic Group). The company specializes in advanced surgical and medical care, including cardiology, oncology, orthopedics, urology, and organ transplantation. Recent strategic highlights include the launch of Sri Lanka’s first AI-enabled robotic surgical system, the expansion of Liver and Kidney Transplant Programmes, and the establishment of a dedicated Hair Transplant Unit. 

Financially, the company has demonstrated a robust post-crisis recovery, with significant improvements in profitability, operational efficiency, and revenue generation. Despite a challenging macroeconomic environment characterized by inflation, currency depreciation, and high utility costs, strategic investments in advanced medical technologies and medical tourism have positioned the company for sustainable long-term growth. 

**Key periods covered:** Q2 2023 to Q2 2026 (Natural calendar years and quarters derived from period end dates).

## Financial Performance

### Revenue and Profitability Trends
*Note: Values are stated in LKR Millions.*

| Period | Revenue | Gross Profit | Net Profit/Loss | GP Margin | NP Margin |
|--------|---------|--------------|-----------------|-----------|-----------|
| **Q2 2026** (Ended Jun 30, 2026) | 2,040.0 | 880.7 | 225.7 | 43.17% | 11.06% |
| **Q1 2026** (Ended Mar 31, 2026) | 1,871.9 | 794.8 | 251.7 | 42.46% | 13.45% |
| **Q4 2025** (Ended Dec 31, 2025) | 1,964.2 | 861.2 | 283.1 | 43.85% | 14.41% |
| **Q3 2025** (Ended Sep 30, 2025) | 1,986.4 | 870.8 | 239.4 | 43.84% | 12.05% |
| **Q2 2025** (Ended Jun 30, 2025) | 1,899.5 | 821.2 | 202.3 | 43.23% | 10.65% |
| **Q1 2025** (Ended Mar 31, 2025) | 1,831.1 | 783.9 | 213.4 | 42.81% | 11.65% |
| **Q4 2024** (Ended Dec 31, 2024) | 1,805.8 | 755.4 | 142.5 | 41.83% | 7.89% |
| **Q3 2024** (Ended Sep 30, 2024) | 1,841.7 | 776.1 | 185.2 | 42.14% | 10.06% |
| **CY 2025/26 Annual** (Ended Mar 31, 2026)| 7,721.6 | 3,493.9 | 940.5 | 45.25% | 12.18% |
| **CY 2024/25 Annual** (Ended Mar 31, 2025)| 7,182.1 | 3,001.2 | 373.7 | 41.79% | 5.20% |

**Analysis:**
*   **Revenue Growth:** The company has experienced consistent revenue growth, achieving a YoY increase of 7.5% in the annual period ending Q1 2026. Quarterly performance remains strong, with Q2 2026 marking the highest quarterly revenue in the observed periods (LKR 2.04B).
*   **Profitability Turnaround:** Net profit for the annual period ending Q1 2026 surged by 151.6% YoY (from LKR 373.7M to LKR 940.5M). This drastic improvement is largely driven by optimized theatre utilization, higher patient volumes, and increased contributions from specialized units (cardiac care, oncology).
*   **Margin Expansion:** Both Gross Profit and Net Profit margins have expanded steadily over the past eight quarters. Cost control, procurement discipline, and increased throughput in high-margin specialized surgeries have successfully counteracted inflation and high operating inputs.

## Balance Sheet Analysis
*Note: Values are stated in LKR Millions.*

| Indicator | As at Jun 30, 2026 (Q2 2026) | As at Mar 31, 2026 (Q1 2026) | As at Mar 31, 2025 (Q1 2025) |
|-----------|------------------------------|------------------------------|------------------------------|
| **Total Assets** | 16,009.9 | 16,523.0 | 14,438.9 |
| **Total Liabilities** | 8,240.5 | 8,390.6 | 7,546.6 |
| **Total Equity** | 7,769.4 | 8,132.4 | 6,892.3 |
| **Net Assets Per Share (LKR)** | 14.70 | 14.36 | 12.25 |

**Analysis:**
*   **Asset Growth:** Total assets grew by 14.4% in the annual period ending Q1 2026, largely driven by capital expenditures on state-of-the-art medical equipment (e.g., robotic surgical systems) and infrastructure upgrades (Super Deluxe Room renovations). 
*   **Leverage:** The company maintains a healthy capital structure. The gearing ratio improved from 0.28x in Q1 2025 to 0.21x by Q1 2026, indicating reduced reliance on debt financing.
*   **Liquidity:** Cash and bank balances improved significantly from LKR 336.4M in Q1 2025 to LKR 651.4M in Q1 2026, providing a buffer against macroeconomic shocks.

## Cash Flow Analysis
*Note: Values are stated in LKR Millions for annual periods ending March 31.*

| Cash Flow Category | Annual ending Mar 31, 2026 (Q1 2026) | Annual ending Mar 31, 2025 (Q1 2025) |
|--------------------|--------------------------------------|--------------------------------------|
| **Operating Cash Flow** | 425.4 | (122.7) |
| **Investing Cash Flow** | 64.4 | 475.9 |
| **Financing Cash Flow** | (554.4) | (429.0) |
| **Net Change in Cash** | (64.5) | (75.8) |

**Analysis:**
*   **Operating Recovery:** Operating cash flow saw a massive turnaround, moving from a deficit of LKR 122.7M to a positive LKR 425.4M. This indicates strong cash generation from core hospital operations.
*   **Capital Expenditure:** The company incurred LKR 520.8M in capital expenditure during the year ending Q1 2026, affirming management's commitment to upgrading clinical infrastructure.
*   **Debt Servicing:** Significant outflows in financing cash flows represent the repayment of interest-bearing loans and borrowings (LKR 3.73B repaid vs. LKR 3.19B obtained), actively reducing the overall debt burden.

## Key Financial Ratios and Growth Indicators

| Metric | CY 2025/26 (Ended Q1 2026) | CY 2024/25 (Ended Q1 2025) |
|--------|----------------------------|----------------------------|
| **Return on Equity (ROE)** | 12.40% | 5.77% |
| **Earnings Per Share (EPS)** | LKR 1.54 | LKR 0.50 |
| **Price-to-Earnings (P/E)** | 10.00x | 23.00x |
| **Gearing Ratio** | 0.21 | 0.28 |
| **Quick Asset Ratio** | 0.70 | 0.89 |

**Growth & Strategic Indicators:**
*   **Technological Milestones:** Implemented Sri Lanka's first robotic surgery program, providing a significant competitive advantage.
*   **New Services:** Expansion of structural heart interventions (TAVI, MIDCAB), oncology, and newly formed clinics (Breast, Lymph Node, Hair Transplant).

## Economic and Market Context
*   **Macro Environment:** Sri Lanka is undergoing a gradual economic recovery characterized by macroeconomic stability and easing inflationary pressures. However, the private healthcare sector faces high taxation, elevated utility costs, and the depreciation of the Rupee, which inflates the cost of imported medicines and equipment.
*   **Market Opportunity (Medical Tourism):** The company is actively positioning itself as a hub for medical tourism to capitalize on regional demand and the Sri Lankan diaspora. Advanced surgeries (robotic, transplant, cardiac) offered at a competitive cost compared to global benchmarks are expected to generate robust foreign exchange earnings.

## Future Potential and Outlook
*   **Clinical Expansions:** The first robotic-assisted procedures are slated to commence in early 2026. The continued maturation of the Liver and Kidney Transplant Programs and the newly established Hair Transplant unit provides multiple new high-margin revenue streams.
*   **Infrastructure:** Completion of premium inpatient facility renovations directly caters to high-net-worth local patients and international medical tourists.
*   **Strategic Focus:** Management's stated objective is to build depth around existing capabilities, focusing on minimally invasive surgery and specialized clinical pathways.

## Risks and Challenges
*   **Regulatory & Pricing Pressures:** The Ministry of Health and Consumer Affairs Authority regulate certain healthcare prices. Inability to pass on rising utility, manpower, and imported consumable costs to patients could compress margins.
*   **Supply Chain Resilience:** Historical foreign exchange volatility and import restrictions pose risks to the continuous availability of critical medicines and consumables. *Mitigation:* The company has increased safety stock levels for selected medications from 3 to 6 months.
*   **Climate & Environmental:** Extreme weather events (e.g., Cyclone Ditwah) pose physical risks to infrastructure and supply chains. However, recent events showed no material financial impact, and the company is reinforcing its disaster recovery plans.

## Shareholder and Corporate Information
*   **Major Shareholder:** Asiri Hospital Holdings PLC controls 79.96% of the shares (reduced slightly in recent periods but remains the controlling parent).
*   **Public Holding:** Free float is approximately 20.04% distributed among 4,013 shareholders. 
*   **Recent Market Performance:** The stock experienced significant volatility. Over the last 90 trading sessions (ending Aug 31, 2026), the stock price saw a severe contraction, returning **-42.15%**, dropping from LKR 24.20 to close at **LKR 14.00**. 
*   **Dividends:** No dividends were declared in the latest reported period (CY 2025/26), compared to LKR 0.30 per share in the prior year, likely to retain capital for debt repayment and robotic surgery investments.

## Investment Decision Indicators

**Strengths:**
*   **Dominant Market Position:** First-mover advantage in AI-enabled robotic surgery in Sri Lanka.
*   **Surging Profitability:** 151% increase in net profit, expanding margins, and strong turnaround in operating cash flow.
*   **Deleveraging:** Healthy and improving gearing ratio (0.21), with active debt repayment.
*   **Diversification:** Highly lucrative new service lines (Organ Transplants, Medical Tourism).

**Weaknesses:**
*   **Recent Stock Price Crash:** A 42% drop in the share price over the last 90 trading sessions indicates poor short-term market sentiment or potential broader market sell-offs.
*   **No Yield:** Suspension of dividend payments in the most recent year may deter income-seeking investors.
*   **Cost Vulnerability:** High reliance on imported medical equipment and consumables exposes the company to FX risks.

**Opportunities and Threats:**
*   *Opportunity:* Medical tourism represents a massive, untapped foreign exchange revenue stream.
*   *Threat:* Regulatory price caps on medical services amidst rising local inflation/utility costs could abruptly halt margin expansion.
*   *Threat:* "Brain drain" or shortage of specialized medical personnel in Sri Lanka due to macroeconomic pressures.

**Overall Assessment:**
**Rationale for BUY:** The underlying fundamentals of the company are exceptionally strong. P/E has contracted to an attractive 10.00x, ROE has doubled to 12.40%, and net profit margins are expanding. The recent -42% drop in share price presents a steep discount to a company that is actively capturing monopoly-like advantages in advanced robotic and transplant surgery in its region. 
**Rationale for HOLD:** Investors may wish to wait for the stock price to stabilize following the recent 90-day downward trend. While profitability is excellent, the lack of dividend payouts and sensitivity to Sri Lanka's fragile macroeconomic recovery and FX rates pose lingering risks. 
**Rationale for SELL:** If the recent stock plunge is indicative of undisclosed institutional exits or anticipated macroeconomic deterioration in Sri Lanka that will freeze elective surgeries or cause price-cap regulations to bite into the newly expanded margins.